Cargando…

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex

Detalles Bibliográficos
Autores principales:	Zloza, Andrew, Broucek, Joseph R, Huelsmann, Erica J, Hughes, Tasha, Kaufman, Howard L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990301/ http://dx.doi.org/10.1186/2051-1426-1-S1-P266

Ejemplares similares

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014)

Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015)

PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses
por: Huelsmann, Erica, et al.
Publicado: (2013)

Single-step nanoparticle antigen presentation system for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells
por: Kim, Dae Won, et al.
Publicado: (2014)

The impact of age on a mitoxantrone-based tumor vaccine
por: Stonewall, Keven, et al.
Publicado: (2013)

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade
por: Kohlhapp, Frederick J, et al.
Publicado: (2015)

Stable disease, diagnosis and dose are prognostic factors for survival after interleukin-2 immunotherapy
por: Kwan, Nathan H, et al.
Publicado: (2015)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)

Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy
por: Agrawal, Shruti, et al.
Publicado: (2015)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
por: Chandar, Ashwin, et al.
Publicado: (2015)

Interleukin-4 receptor targeted immunotherapy of human bladder cancer in animal models
por: Joshi, Bharat H, et al.
Publicado: (2014)

Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2015)

Erratum: Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2016)

Goldilocks and the three bears
por: Arengo, Sue
Publicado: (2011)

Goldilocks and the three TILs
por: Dada, Hannah, et al.
Publicado: (2022)

Goldilocks meets Polycomb
por: Verrijzer, C. Peter
Publicado: (2022)

Identification of new manioc allergens and successful oral immunotherapy in a Brazilian allergic patient
por: Santos, KS, et al.
Publicado: (2013)

Goldilocks, vitamin D and sarcoidosis
por: Baughman, Robert P, et al.
Publicado: (2014)

The Goldilocks zone in neural circuits
por: Humphries, Mark D
Publicado: (2016)

A bacterial Goldilocks mechanism
por: Kim, Irene M, et al.
Publicado: (2020)

Goldilocks and the BCG: Bacillus Calmette-Guérin Dose Reduction in the Age of Shortage
por: Nikas, Christine V., et al.
Publicado: (2020)

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
por: Chu, Melinda, et al.
Publicado: (2015)

Generation of interleukin-13 receptor alpha2 antigen expressing modified vaccinia ankara recombinant virus for potential cancer immunotherapy
por: Sato, Yuki, et al.
Publicado: (2014)

Pro-B-type natriuretic peptide predicts mortality in critically ill patients
por: Meyer, B, et al.
Publicado: (2005)

Immunotherapy generates selective pressure for acquisition of immunogenic neoantigens in escape tumors
por: Pan, Jenny H, et al.
Publicado: (2015)

Development of an adoptive cell therapy protocol with tumor-infiltrating lymphocytes and intermediate-dose interleukin-2 therapy
por: Nguyen, Linh T, et al.
Publicado: (2013)

Role of MRI as a problem-solving tool in screening assessment
por: Locke, RK, et al.
Publicado: (2011)

Motion-based predictive coding is sufficient to solve the aperture problem
por: Khoei, Mina A, et al.
Publicado: (2011)

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
por: Kaufman, Howard L, et al.
Publicado: (2014)

Activity of dose-dense outpatient intravenous Interleukin-2 preceded by famotidine in metastatic clear cell cancer of the kidney
por: Quan, Walter, et al.
Publicado: (2013)

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020)

Goldilocks and the Raster Grid: Selecting Scale when Evaluating Conservation Programs
por: Avelino, Andre Fernandes Tomon, et al.
Publicado: (2016)

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4fb743o9bq7hc4qqdd14685iup